Intercure Scientific Advisory Board convenes to review company's resperate medical device for hypertension

July 23, 2001

Princeton, NJ, July 23 - InterCure, Ltd. (, an innovative medical technology company, convened its Scientific Advisory Board (SAB) to focus on the company's RESPeRATE ( medical device, during the recent annual meeting of the American Society of Hypertension.

"We were grateful for this opportunity to meet with our world-class Scientific Advisory Board," explained Paul Sheils, Chief Executive Officer of InterCure. "These are some of the world's most distinguished experts on hypertension and the people involved in setting the guidelines and standards for the medical community to manage hypertension. It means a great deal that they support RESPeRATE as an effective treatment of hypertension."

The Scientific Advisory Board (SAB) is composed of several of the world's most renowned opinion-leaders in the field of hypertension, including:

Henry R. Black, M.D., Head of the Preventive Medicine Department at Rush University, Chicago, IL, who served on the Executive Committee of the Sixth Joint National Committee on the Detection, Evaluation, and Treatment of Hypertension (JNC VI), served on the Executive Committee of the American Heart Association Council on High Blood Pressure Research, and was a member of the Executive Committee of the American Society of Hypertension;

Jay N. Cohn, M.D., Professor of Medicine, Cardiovascular Division, Department of Medicine at the University of Minnesota Medical School in Minneapolis, President of the Heart Failure Society of America, President of the International Society of Hypertension, past President of The American Society of Hypertension, former officer of the American Heart Association, and former chairman of the Cardiorenal Advisory Committee of the Food and Drug Administration;

Ehud Grossman, M.D., Head of the Department of Internal Medicine at the Chaim Sheba Medical Center, Tel-Hashomer, Israel, who serves on the council of the Israeli Society of Hypertension, recognized as a hypertension specialist of the European Society of Hypertension, and serves as a consultant in hypertension to the two largest HMOs in Israel, Kupat Holim and Maacabi in Israel;

Joseph L. Izzo, M.D., Professor of Medicine and Professor of Pharmacology & Toxicology at the University of Buffalo, NY, and Vice Chair of Research for the Department of Medicine, who sits on the American Heart Association's Continuing Education Committee and has published extensively in areas such as the mechanisms of hypertension and stress responses of blood pressure;

Giuseppe Mancia, M.D., Professor of Medicine at the University of Milan-Bicocca, Italy and Chairman of the Department of Medicine at the S. Gerardo Hospital, Monza, Milan., Italy, who served as President and Secretary of the International Society of Hypertension, served as President of the Italian Society of Hypertension, is President of the European Society of Hypertension (ESH), and is a member of the Executive Scientific Council of the American Society of Hypertension; and

Thomas Pickering, M.D., PhD, FRCP, Director of the Integrative and Behavioral Cardiology Program of the Cardiovascular Institute at Mount Sinai School of Medicine, New York, author of the Sixth Report of the Joint National Committee for Prevention, Detection, Evaluation and Treatment of Hypertension (JNC VI), member of the American Heart Association's Council for High Blood Pressure Research, who served as Secretary of the American Society of Hypertension, and on the National Heart, Lung and Blood Institute's task forces on hypertension and behavioral medicine.

The members of the Scientific Advisory Board were also joined by other opinion leaders including Norman Kaplan, M.D. (The University of Texas Southwestern Medical Center at Dallas), Talma Rosenthal, M.D. (Tel Aviv University's Sackler Faculty of Medicine), Gianfranco Parati, M.D. (Istituto Scientifico Ospedale S. Luca, Istituto Auxologico Italiano, Milan, Italy), and Reuven Viskoper, M.D. (Barzilai Medical Centre, Ashkelon, Israel).

The advisory board meeting was held to review the clinical progress and to advise InterCure leadership as to how to best help patients with its innovative therapeutic device technology. "We were pleased to update the Board with the progress and results of six clinical studies in the U.S. and abroad. They were very excited to review the efforts underway which study how breathing exercises may modify the cardiovascular system," said Dr. Benjamin Gavish, the Chief Scientist of InterCure and the inventor of the RESPeRATE technology, "This is further strengthening evidence of RESPeRATE's effectiveness as another non-drug option to lower high blood pressure."

RESPeRATE ( received market clearance from the US Food and Drug Administration (FDA) for the adjunctive treatment of hypertension. RESPeRATE is the first non-invasive, non-drug therapeutic device indicated for the adjunctive treatment of hypertension. In controlled clinical trials, RESPeRATE has been demonstrated to reduce blood pressure, with no side effects.

"RESPeRATE offers an exciting new option, in fact, a whole new therapeutic class for the treatment hypertension", noted Dr. Cohn. "The potential for both patients and physicians to benefit from this non-pharmacological treatment to lower blood pressure with no side effects makes RESPeRATE an extremely attractive alternative."

Cumulatively, these seven hypertension experts on the InterCure board have published hundreds of peer-reviewed studies and textbooks on various aspects of cardiovascular diseases. Dr. Black sits on the editorial board of the Journal of Hypertension and the Journal of Human Hypertension. Dr. Cohn is editor-in-chief of the Journal of Cardiac Failure and co-authored the classic text, Cardiovascular Medicine. Dr. Mancia has been a member of the editorial boards of more than 30 international hypertension journals, has been chief or associate editor of various international hypertension journals and is presently deputy editor of the Journal of Hypertension. Cambridge and Oxford-educated Dr. Pickering, who founded the Hypertension Network and to help individuals with high blood pressure take charge of their condition, is on the editorial board of several journals in the fields of hypertension and behavioral medicine. Dr. Izzo is on the Editorial Board of the American Journal of Hypertension and the Journal of Clinical Hypertension. Dr. Grossman serves on the on the editorial board of the Journal of Human Hypertension.
About InterCure

InterCure ( is an innovative medical device company developing a whole new class of non-drug treatments for some of the world's most widespread and costly diseases. The company has patented a proprietary technology platform, which, based upon strong clinical evidence, is being used to develop innovative therapeutic medical devices to treat chronic diseases including hypertension, congestive heart failure (CHF), asthma, and chronic obstructive pulmonary diseases (COPD). InterCure utilizes a web-based reporting and support system to link its therapeutic devices with home diagnostic devices to increase compliance, provide physicians meaningful information and reduce healthcare costs.

For more information on InterCure or RESPeRATE, visit or call 1-877-988-9388.

Marcus Communications

Related Blood Pressure Articles from Brightsurf:

Children who take steroids at increased risk for diabetes, high blood pressure, blood clots
Children who take oral steroids to treat asthma or autoimmune diseases have an increased risk of diabetes, high blood pressure, and blood clots, according to Rutgers researchers.

High blood pressure treatment linked to less risk for drop in blood pressure upon standing
Treatment to lower blood pressure did not increase and may decrease the risk of extreme drops in blood pressure upon standing from a sitting position.

Changes in blood pressure control over 2 decades among US adults with high blood pressure
National survey data were used to examine how blood pressure control changed overall among U.S. adults with high blood pressure between 1999-2000 and 2017-2018 and by age, race, insurance type and access to health care.

Transient increase in blood pressure promotes some blood vessel growth
Blood vessels are the body's transportation system, carrying oxygen and nutrients to cells and whisking away waste.

Effect of reducing blood pressure medications on blood pressure control in older adults
Whether the amount of blood pressure medications taken by older adults could be reduced safely and without a significant change in short-term blood pressure control was the objective of this randomized clinical trial that included 534 adults 80 and older.

Brain blood flow sensor discovery could aid treatments for high blood pressure & dementia
A study led by researchers at UCL has discovered the mechanism that allows the brain to monitor its own blood supply, a finding in rats which may help to find new treatments for human conditions including hypertension (high blood pressure) and dementia.

Here's something that will raise your blood pressure
The apelin receptor (APJ) has been presumed to play an important role in the contraction of blood vessels involved in blood pressure regulation.

New strategy for treating high blood pressure
The key to treating blood pressure might lie in people who are 'resistant' to developing high blood pressure even when they eat high salt diets, shows new research published today in Experimental Physiology.

Arm cuff blood pressure measurements may fall short for predicting heart disease risk in some people with resistant high blood pressure
A measurement of central blood pressure in people with difficult-to-treat high blood pressure could help reduce risk of heart disease better than traditional arm cuff readings for some patients, according to preliminary research presented at the American Heart Association's Hypertension 2019 Scientific Sessions.

Heating pads may lower blood pressure in people with high blood pressure when lying down
In people with supine hypertension due to autonomic failure, a condition that increases blood pressure when lying down, overnight heat therapy significantly decreased systolic blood pressure compared to a placebo.

Read More: Blood Pressure News and Blood Pressure Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to